Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 12Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 61Gastrointestinal 23CNS 10Tumor-Agnostic 8Breast 8Head & Neck 7Sarcoma 5Genitourinary 5NET 3Endocrine 3Myeloid 2Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Dermatologic 1Classical hematology 1

Conditions

Ovarian Neoplasms 1

Interventions

Paclitaxel 69Carboplatin 66Cisplatin 36pembrolizumab 34Gemcitabine 24liposomal doxorubicin 23Cyclophosphamide 23Topotecan 22Bevacizumab 20Taxes 14Docetaxel 13niraparib 12Nivolumab 12olaparib 10fludarabine 10Doxorubicin 9Surveys and Questionnaires 8Radiotherapy 8Oxaliplatin 8aldesleukin 7Filgrastim 7rucaparib 6oregovomab 6fludarabine phosphate 6durvalumab 6avelumab 6Interleukin-2 6Hyperthermic Intraperitoneal Chemotherapy 6Fluorodeoxyglucose F18 6Cytoreduction Surgical Procedures 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Erlotinib Hydrochloride × Gynecologic × Clear all
NCT01003938 2016-06-30

Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer

NYU Langone Health

Phase 2 Terminated
6 enrolled 7 charts
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡